Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Green light for GeneWeave

How GeneWeave technology fits Roche's plans to combat antimicrobial resistance

Roche is buying GeneWeave Biosciences Inc. to beef up the diagnostics side of its infectious disease initiative with a platform to identify bacteria - and antibiotics effective against them - in time to guide treatment decisions. The biotech's Smarticles technology identifies bacteria by making the suspect species or family express a light-producing protein, then reveals susceptibility when an antibiotic dims the glow.

Roche Molecular Diagnostics Head Paul Brown said the deal is the latest the company has done to bring in technologies to tackle the problem of antimicrobial resistance.

"Antimicrobial resistance is one of the biggest health crises facing the globe. It's a problem that is really a very

Read the full 1097 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers